Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Study
100%
Antibody-drug Conjugate
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Targeting Antibodies
100%
Monomethyl Auristatin E
100%
SLC44A4
100%
Auristatin
100%
Maximum Tolerated Dose
75%
Dose Expansion
75%
Diarrhea
50%
Hyperglycemia
50%
Expansion Cohort
50%
Adverse Events
50%
Further Development
25%
Dose Escalation
25%
Dose-limiting Toxicity
25%
Hypoxia
25%
Etiology
25%
Antitumor Activity
25%
Circulating Tumor Cells
25%
Immunogenicity
25%
Microtubules
25%
Pharmacokinetic Properties
25%
Stable Disease
25%
Neutropenia
25%
Bacteremia
25%
Leukopenia
25%
Constipation
25%
Systemic Toxicity
25%
Abdominal Pain
25%
Partial Response
25%
Recommended Phase 2 Dose
25%
Renal Insufficiency
25%
Troponin Elevation
25%
Hyponatremia
25%
Cardiac Sequelae
25%
Expansion Process
25%
Repeated Dosing
25%
Narrow Therapeutic Index
25%
Maculopapular Rash
25%
On-target Effects
25%
Dose Level
25%
Pharmacology, Toxicology and Pharmaceutical Science
Antibody Drug Conjugate
100%
Castration Resistant Prostate Cancer
100%
Vedotin
100%
Maximum Tolerated Dose
75%
Diarrhea
50%
Adverse Event
50%
Hyperglycemia
50%
Immunogenicity
25%
Antitumor Activity
25%
Hypoxia
25%
Bloodstream Infection
25%
Kidney Failure
25%
Constipation
25%
Abdominal Pain
25%
Neoplasm
25%
Neutropenia
25%
Troponin
25%
Leukopenia
25%
Hyponatremia
25%
Therapeutic Window
25%
Maculopapular Rash
25%
Pharmacokinetics
25%
Diseases
25%
Etiology
25%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Antibody-Drug Conjugate
100%
Monomethyl Auristatin E
100%
Adverse Event
50%
Diarrhea
50%
Hyperglycemia
50%
Circulating Tumor Cell
25%
Hypoxia
25%
Sequela
25%
Neutropenia
25%
Pharmacokinetics
25%
Renal Failure
25%
Bloodstream Infection
25%
Constipation
25%
Abdominal Pain
25%
Microtubule
25%
Antineoplastic Activity
25%
Hyponatremia
25%
Leukopenia
25%
Maculopapular Rash
25%
Troponin
25%
Immunogenicity
25%
Therapeutic Window
25%
Diseases
25%
Etiology
25%